HOMOEOPATHIC TREATMENT IN FATTY LIVER DISEASE

ANALYTICAL CHARACTERIZATION OF CARDUUS MARIANUS MOTHER TINCTURE AND ITS EFFECTIVENESS IN COMPARISON WITH INDIVIDUALIZED HOMOEOPATHIC MEDICINE IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE: AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105587

Enrollment

Registered

2026-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: CARDUUS MARIANUS MOTHER TINCTURE: 20 drops/day for 3 months, administered orally Control Intervention1: Individualized Homoeopathic Medicine: prescribed according to the totality of sym

Eligibility

Inclusion criteria

Inclusion criteria: 1. All religion and all socio-economic status 2. Diagnosed cases of NAFLD (Grade I and II) by ultrasonography as per American Gastroenterological Association 3. Fulfilling the diagnostic criteria of American Association for the Study of Liver Diseases 4. Participants who are willing to give written informed consent 5. Participants who are able to understand either hindi or english

Exclusion criteria

Exclusion criteria: 1. Patients with complications of hepatic steatosis like liver cirrhosis, hepatocellular carcinoma. 2. Adults who had a history of heart attack or stroke, or other atherosclerotic disease. 3. Patients with uncontrolled systemic diseases like HTN, DM, Hypothyroidism etc. 4. Pregnant and lactating women 5. Psychologically ill patients 6. Immunocompromized partients 7. Participants undergoing homoeopathic or any other treatment for any other chronic disease for last 6 months 8. Simultaneous participation in any other clinical trial.

Design outcomes

Primary

Measure	Time frame
CLDQ-NASH scores (The chronic liver disease questionnaire for nonalcoholic steatohepatitis (CLDQ-NASH) was developed in a systematic manner for assessment of patient-reported outcomes. This instrument collects data on 36 items grouped into 6 domains: abdominal symptoms, activity/energy, emotional health, fatigue, systemic symptoms, and worry.)Timepoint: assessed at baseline and after 3 months of intervention	—

Measure

Time frame

CLDQ-NASH scores (The chronic liver disease questionnaire for nonalcoholic steatohepatitis (CLDQ-NASH) was developed in a systematic manner for assessment of patient-reported outcomes. This instrument collects data on 36 items grouped into 6 domains: abdominal symptoms, activity/energy, emotional health, fatigue, systemic symptoms, and worry.)Timepoint: assessed at baseline and after 3 months of intervention

—

Secondary

Measure	Time frame
Comparing the mean value of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)Timepoint: assessed at baseline and after 3-months of intervention;Fibrosis risk calculated using the FIB-4 IndexTimepoint: assessed at baseline and after 3-months of intervention;Modified Naranjo Criteria for Homeopathy (MONARCH)Timepoint: after 3-months of intervention	—

Countries

India

Contacts

Public ContactDr Shakira Ashraf

National Institute of Homooeopathy, Delhi

drrajib.nih@gmail.com9748925539

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026